Related Experiment Video

Updated: Mar 30, 2026

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes
08:35

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Published on: July 17, 2021

23.5K

Association between apolipoprotein B gene polymorphisms and the risk of coronary heart disease (CHD): an update

Jing-Zhan Zhang1, Ying-Ying Zheng1, Yi-Ning Yang1

  • 1Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|November 6, 2015
PubMed

Insights

Genetic variations in apolipoprotein B (apoB) influence coronary heart disease (CHD) risk. This meta-analysis confirms that apoB EcoRI and SpIns/Del polymorphisms are associated with increased CHD risk, while XbaI shows no significant link.

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology

Background:

  • Apolipoprotein B (apoB) gene polymorphisms are implicated in coronary heart disease (CHD) risk.
  • Previous studies show conflicting results regarding the association between apoB polymorphisms and CHD.

Purpose of the Study:

  • To conduct a meta-analysis to precisely estimate the relationship between apoB genetic polymorphisms and CHD.
  • To clarify the conflicting findings on apoB gene variants and their impact on CHD susceptibility.

Main Methods:

  • Systematic literature search across multiple databases (PubMed, Web of Science, Google Scholar, etc.) for relevant studies.
  • Inclusion of 54 studies encompassing 7236, 10,912, and 14,102 individuals for EcoRI, XbaI, and SpIns/Del polymorphisms, respectively.
  • Meta-analysis performed using RevMan 5.0 software to pool data and assess associations.

Main Results:

  • Significant association found between apoB EcoRI polymorphism and CHD risk across allelic, dominant, and recessive models (p < 0.05).
  • A similar association was observed between apoB SpIns/Del polymorphism and CHD.
  • No significant association was detected between apoB XbaI polymorphism and CHD risk.

Conclusions:

  • The meta-analysis supports an association between apoB EcoRI and SpIns/Del polymorphisms and an elevated risk of CHD.
  • The apoB XbaI polymorphism did not show a significant association with CHD in this comprehensive analysis.
Abstract

Keywords:
Apolipoprotein B (apoB) gene polymorphismcoronary heart diseasemeta-analysis

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
77
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
123
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.6K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K